Overview

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Status:
Completed

Trial end date:
2003-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.

Phase:

Phase 2

Details

Lead Sponsor:

Achillion Pharmaceuticals
Alexion Pharmaceuticals

Collaborator:

Achillion, a wholly owned subsidiary of Alexion

Treatments:

Antiviral Agents
Lamivudine